MoonLake Immunotherapeutics announces landmark Phase 2 results for Nanobody® sonelokimab in active psoriatic arthritis
All key secondary endpoints were met for the 60mg and 120mg doses with induction. The key secondary endpoint Psoriasis Area and Severity Index (PASI) 90 was met for all doses
- First placebo-controlled randomized trial in active psoriatic arthritis (PsA) using a Nanobody® to report positive topline results in support of potential best-in-class profile
- Primary endpoint ACR50 met with up to 47% (p
- Primary endpoint ACR50 met with up to 47% (p
- Contact Email
- [email protected]
- Issued By
- Knowledge Bylanes
- Business Address
- Press Centre
Karachi Pakistan - Country
- Pakistan
- Categories
- Miscellaneous
- Last Updated
- November 7, 2023